cardiac failure

Mitral Valve Repair with MirtaClip Was Feasible and Safe

Transcatheter mitral valve repair (TMVR) with MitraClip was shown feasible and safe, and therefore a viable option for symptomatic patients with severe mitral valve regurgitation of prohibitive risk. In this regard, the procedure alleviates symptoms, cardiac regurgitation and has a potential benefit on ventricular remodeling. However, many patients presented atrial fibrillation (AF) and mitral valve<a href="https://solaci.org/en/2019/04/10/mitral-valve-repair-with-mirtaclip-was-feasible-and-safe/" title="Read more" >...</a>

acceso

Transcaval Access Is Safe in TAVR

Courtesy of Dr. Carlos Fava. One of the limitations to percutaneous interventions is poor or impossible femoral access. This happens especially in TAVR, with endoprosthesis or ventricular assistance devices, when the transcaval approach with cardiac occluder rises as a viable alternative. We have started to use it in TAVR, but at present there is little<a href="https://solaci.org/en/2019/03/29/transcaval-access-is-safe-in-tavr/" title="Read more" >...</a>

ACC 2019 | PARTNER 3: TAVI en bajo riesgo con menos eventos al año que la cirugía

ACC 2019 | PARTNER 3: Low Risk TAVR vs. Surgery, Fewer Events per Year

Courtesy of Dr. Carlos Fava. TAVR has largely been shown superior or non-inferior in high or intermediate risk patients.  Indeed, the development of new technologies, the more simplified procedure and the increased experience of operators and team have allowed these groups to benefit from this strategy. However, there is little evidence available on low risk<a href="https://solaci.org/en/2019/03/19/acc-2019-partner-3-low-risk-tavr-vs-surgery-fewer-events-per-year/" title="Read more" >...</a>

¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

Un Underestimated Symptom of Aortic Stenosis

For the first time, this long term observational study on a large cohort of contemporary patients with aortic stenosis (AS), has shown syncope is an underestimated threat, associated with worse prognosis after surgical aortic valve replacement (SAVR). It is interesting to note that other symptoms or early signs of AS that will normally indicate SAVR<a href="https://solaci.org/en/2019/02/11/un-underestimated-symptom-of-aortic-stenosis/" title="Read more" >...</a>

MitraClip: ¿debemos intervenir antes a nuestros pacientes?

Continuous Monitoring of Left Atrial Pressure during MitraClip, Regardless Echocardiography

The aim of this study was to assess the use of measuring left atrial pressure to complement transesophageal echocardiography and doppler imaging. Procedure efficacy is measured in the cath lab by echocardiography. However, these measurements are operator dependent and might be influenced by left ventricular function and changes in left atrial compliance. &nbsp; The study<a href="https://solaci.org/en/2019/01/04/continuous-monitoring-of-left-atrial-pressure-during-mitraclip-regardless-echocardiography/" title="Read more" >...</a>

Can We Discontinue Betablockers after AMI?

Betablockers (BB) were the first drugs shown to effectively reduce events after acute MI. However, reperfusion and other secondary prevention drugs that came along after that have cast a shadow on betablockers’ original benefit. This study looked at betablocker discontinuation after acute MI in patients with no cardiac failure optimally treated with all recommended medication.<a href="https://solaci.org/en/2018/12/10/can-we-discontinue-betablockers-after-ami/" title="Read more" >...</a>

AHA 2018 | DES de última generación similares a los de 2° generación más allá del polímero

AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer

Sirolimus-eluting stents with biodegradable polymer did not offer better outcomes compared with instant-classic (and undoubtedly valid) everolimus-eluting stents with durable polymer such as Xience. New-generation drug-eluting stents (DES) offer better outcomes than first-generation devices after a 10-year follow-up, according to the ISAR-TEST 4 trial presented at the American Heart Association (AHA) Congress Scientific Sessions and published<a href="https://solaci.org/en/2018/11/30/aha-2018-new-generation-des-are-similar-to-second-generation-des-beyond-polymer/" title="Read more" >...</a>

AHA 2018 | El dispositivo Impella gana evidencia, pero hacen faltan estudios más grandes

AHA 2018 | More Evidence for the Impella Device, But Larger Trials Are Necessary

In this pilot study, unloading the left ventricle with the Impella CP circulatory support device and delaying angioplasty by about 30 minutes appeared to be feasible and safe in patients with acute myocardial infarction without cardiogenic shock. This work sought to test the hypothesis that the device reduces ischemia-reperfusion injury. The trial included 50 patients who had the<a href="https://solaci.org/en/2018/11/30/aha-2018-more-evidence-for-the-impella-device-but-larger-trials-are-necessary/" title="Read more" >...</a>

Infarto agudo de miocardio y lesiones de múltiples niveles

Cautious Administration of Supplemental 02, Especially in Acute Stroke or MI

Recent studies show the potential damaging effect of supplemental oxygen in the context of acute stroke and myocardial infarction. Experts now say that it should not be used in patients with &gt;92% oxygen saturation. These guidelines have looked into the most recent studies, including the DET02X-AMI, which suggest supplemental oxygen therapy could increase mortality in<a href="https://solaci.org/en/2018/11/21/cautious-administration-of-supplemental-02-especially-in-acute-stroke-or-mi/" title="Read more" >...</a>

Mortalidad a un año en infarto post PCI

ICELAND MI: Unrecognized MI Have Similar Prognosis to Recognized MI

At 10-year follow-up, unrecognized or silent MIs have similar mortality to clinically recognized MI and, even though this does not justify routine screening, these findings call for more aggressive prevention.   Unrecognized MI, detected by MRI, is associated to long term mortality risk similar to that of recognized MI; therefore, these patients have higher risk<a href="https://solaci.org/en/2018/10/29/iceland-mi-unrecognized-mi-have-similar-prognosis-to-recognized-mi/" title="Read more" >...</a>

Top